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This finding also provides strong additional support for our hypothesis that ERRα's transcriptional activity is regulated in part via HER2 signaling (9) . In other words, over-expression of HER2 makes MCF-7 cells resistant to killing by tamoxifen in part by inducing phosphorylation of ERRα, switching the latter from its repressor to activator state; incubation with XCT790 reverses this phenotype by knocking down expression of ERRα in the cells. Now that we have successfully identified a cell line with these desired properties, we should be able in the near future to achieve Task 2 by infecting MCF-7/HER2-18 cells with a lentivirus that expresses an shRNA against ERRα and isolating clonal derivatives of these cells that have reduced levels of ERRα and are, once again, sensitive to killing by tamoxifen.
Specific Aim #2 -Identify some key cellular genes involved in growth control whose promoter regions are bound by ERα-ERRα heterodimers.
A necessary prerequisite for achieving Aim 2 involved identifying an ERRα-specific antibody that meets the gold standard for use in ChIP-seq experiments, i.e., chromatin immunoprecipitation followed by sequencing of the specific DNA sites bound by ERRα. Thus, we first set out to finalize our characterization, publication, and licensing to biotechnology companies of our previously isolated panel of 9 mouse monoclonal antibodies (mAbs) specific to ERRα. This work has now been completed. We recently published an article describing the isolation and extensive characterization of these nine antibodies (17; Appendix 1). We have also successfully licensed our panel of ERRα-specific mAbs to Santa Cruz Biotechnology so they are now readily available to anyone for non-commercial uses. In addition, we optimized reaction conditions for performing ChIP assays using a combination of our ERRα-specific mAbs. With this knowledge in hand, we then collaborated with the laboratory of Dr. Peggy Farnham, a leader in the ENCODE Project. They thoroughly tested some of our antibodies using their ChIP-seq protocols with chromatin obtained from MCF-7 cells grown in standard medium and serum. They found that our ERRα-specific mAb 2ERR7 met their "gold standard" for use in ChIP-seq experiments, including confirming that ERRα bound strongly to its own promoter. They then used these data to tentatively identify 5,119 peaks on the human genome that appear to be bound by both ERRα and ERα. Thus, we are now very well positioned to achieve Task 3, i.e., identify by ChIP-seq specific sites that are bound by both ERα and ERRα in a tamoxifen-dependent manner in the genomes of the MCF-7/HER2-18 cell lines identified in Aim 1 as dependent upon ERRα for tamoxifen resistance; we hope to do so in the near future. .
Specific Aim #3 -Test whether expression of these above-identified genes is, indeed, regulated, in part, by the combination of these two hormone receptors together with tamoxifen. 
CONCLUSIONS
Here, we set out to test our hypothesis that ERRα may play a major role in the etiology or progression of many tamoxifen-resistant breast cancers, doing so by heterodimerizing with ERα and, thus, enabling transcription, despite the presence of tamoxifen, of some key estrogen responsive element (ERE)-regulated genes involved in growth control of breast cells. In strong support of this hypothesis, we identified a breast cancer cell line, MCF-7/HER2-18, that regains sensitivity to killing by tamoxifen when treated with XCT790, a drug that specifically leads to knock down of ERRα protein levels in cells. We also identified an ERRα-specific monoclonal antibody that meets the gold standard for use in ChIP-seq experiments. We began to use it to note putative locations in the human genome that may be sites where ERα-ERRα heterodimers bind in the presence of estrogens and, presumably, tamoxifen to regulate expression of genes that could play key roles in the development of tamoxifen-resistant breast cancer. Thus, our findings well supported our hypothesis. The experiments have proceeding well, but we ran out of time and money to complete all of the ones proposed for this small, 1-year CONCEPT grant. The data obtain should help us to succeed in obtaining a larger grant that requires more preliminary data.
Regarding applications, our findings provide additional evidence that drugs that specifically disrupt formation of ERα-ERRα heterodimers may serve as novel, specific therapeutics for treating patients with tamoxifen-resistant breast cancer. More generally, these studies suggest that patients with aggressive breast cancers, especially tamoxifen-resistant ones for which there are currently no good therapies, may derive more therapeutic benefit from treatment with new or existing drugs (e.g., Herceptin) affecting the activities of ERRα and its target genes rather than from ERα-targeted therapeutics such as tamoxifen. Hopefully, our studies may also lead to the rational development of novel breast cancer prognosticators and predictors of responses to current therapies. Estrogen-related receptor alpha (ERRa) is an orphan nuclear receptor whose elevated expression is thought to contribute to breast, colon, and ovarian cancers. In order to investigate the role of ERRa in human disease, there is a need for immunological reagents suitable for detection and purification of ERRa. We expressed recombinant human ERRa in Escherichia coli, purified the protein, and used it to generate monoclonal antibodies (mAbs) to ERRa. Nine high-affinity mAbs were chosen for their abilities to detect overexpressed ERRa in enzyme-linked immunosorbent assays (ELISAs) and Western blots, after which isotyping and preliminary epitope mapping was performed. The mAbs were all IgG subtypes and reacted with several different regions of full-length ERRa. A majority of the mAbs were found to be useful for immunoprecipitation of ERRa, and several could detect DNA-bound ERRa in electrophoretic mobility supershift assays (EMSAs) and chromatin immunoprecipitation (ChIP). The suitability of mAbs to detect ERRa in immunofluorescence assays was assessed. One mAb in particular, 2ERR10, could specifically detect endogenous ERRa in mammary carcinoma cells. Finally, we performed assays to screen for mAbs that gently release ERRa in the presence of a low-molecular-weight polyhydroxylated compound (polyol) and nonchaotropic salt. Using gentle immunoaffinity chromatography, we were able to isolate ERRa from mammalian cells by eluting with a polyol-salt solution. Our characterization studies show that these monoclonal antibodies perform well in a variety of biochemical assays. We anticipate that these novel reagents will prove useful for the detection and purification of ERRa in research and clinical applications. Ó 2012 Elsevier Inc. All rights reserved.
Introduction
Estrogen-related receptor alpha (ERRa) 1 is a nuclear receptor transcription factor which was discovered in low-stringency screens of cDNA libraries which used the estrogen receptor DNA-binding domain as a probe [1] . Despite its structural similarities with estrogen receptor and other nuclear receptor family members, ERRa is considered to be an orphan receptor because it has no known natural ligand. Its transcriptional activities are thought to be modulated by post-translational modifications and interactions with cofactors [2, 3] . Full-length ERRa consists of 423 amino acids which encode a 46-kDa protein. It comprises four major canonical nuclear receptor domains, indicated by amino acid (aa) position (see Fig. 3B ). The N-terminal A/B domain (aa 1-78) is involved in ligand-independent functions of nuclear receptors. The C region (aa 79-144) contains the DNA-binding domain (DBD), which shares nearly 70% sequence identity with the DBD of estrogen receptor alpha. Like estrogen receptor, ERRa can bind estrogen response elements (EREs) containing the inverse palindromic sequence 5 0 -AGGT-CANNNTGACCT-3 0 ; ERRa can also bind to extended half-site sequences known as estrogen-related response elements (ERREs), which have the general sequence 5 0 -TNAAGGTCA-3 0 [4] [5] [6] [7] [8] . Adjacent to the DBD is the D domain (aa , also known as the hinge region. The C-terminal E/F domain (aa 199-423) typically contains a ligand-binding region for most nuclear receptors; however, phenylalanine residues fill the binding pocket of ERRa, holding it in an active conformation similar to that of estrogen-bound estrogen receptor [9] . It is thought that this structural configura- [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Contents lists available at SciVerse ScienceDirect Protein Expression and Purification j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y p r e p tion is responsible for the hormone-independent activity of ERRa. The E/F domain also contains LXXLL motifs which allow ERRa to interact with cofactors [10] .
ERRa is localized predominantly in cell nuclei and is most highly expressed in skeletal muscle, kidney, heart, brain, and intestine [1, 7, 11] . Recent studies have demonstrated that ERRa regulates transcription of genes involved in metabolism [12] [13] [14] [15] [16] . Elevated ERRa protein levels have been associated with certain breast, endometrial, ovarian, prostate, and colorectal cancers [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , but its exact role in cancer progression is not clear. In order to investigate the contributions of ERRa in disease development, it would be useful to have high-affinity immunological reagents able to detect and purify ERRa in a variety of applications.
To address this need, we generated murine monoclonal antibodies (mAbs) to human recombinant ERRa. Nine high-affinity mAbs were chosen for their abilities to react with ERRa in enzyme-linked immunosorbent assays (ELISAs) and Western blot analyses. We evaluated the capacity of each mAb to react with ERRa in electrophoretic mobility supershift assays (EMSAs), immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), and immunofluorescence (IF) applications. Using gentle immunoaffinity chromatography, we were able to purify overexpressed and endogenous ERRa from mammalian cell lysates in a single chromatographic step. Our characterization studies demonstrate that these mAbs retain high affinity for ERRa and are suitable for use in a wide range of biochemical assays. We anticipate that these immunological reagents will prove useful in research and clinical applications for the detection and purification of ERRa.
Materials and methods

Reagents and buffers
General-purpose molecular biology-grade reagents were obtained from established vendors. Reagents specific to particular applications are indicated in the text.
Expression of His 6 -ERRa in Escherichia coli
The coding region of human full-length ERRa (contained in pcDNA3.1/V5-His, described in [8] ) was amplified using the forward primer 5 0 -GCCACCATGGCATCCAGCCAGGTGGTGGGCATTG-3 0 , which contained an NcoI site (underlined). The reverse primer, 5 0 -CGCTGCGGCCGCGTCCATCATGGCCTCGAGCATC-3 0 , contained a NotI site (underlined). The amplified product was gel-purified and cloned into the NcoI/NotI sites of the pET28b(+) vector (EMD Biosciences, Gibbstown, NJ). This construction resulted in fulllength ERRa containing an in-frame hexahistidine (His 6 ) tag at the C-terminus. The sequence of the insert was confirmed and the plasmid was transformed into E. coli BL21(DE3)pLysS. Trans- Fig. 1 . Purification of His 6 -ERRa. His 6 -tagged full-length ERRa was overexpressed in E. coli and purified on a Ni-NTA column. Purification fractions were separated by SDS-PAGE and stained with Coomassie. Full-length ERRa has a molecular weight of 46 kDa; His 6 -tagged ERRa has an apparent molecular weight of about 49 kDa. formed bacteria were cultured in 500 mL of Luria-Bertani (LB) medium containing 30 lg/mL kanamycin and 35 lg/mL chloramphenicol and grown overnight at 37°C with shaking. Once the cultures reached an O.D. 600 nm of 0.6, they were induced with 1 mM isopropyl-b-D-1-thiogalactopyranoside (IPTG) and grown for an additional 2.5 h, after which the bacterial pellets were harvested and stored at À80°C. The pellet (1 g wet weight of cells) was resuspended in 8 mL 1Â His binding buffer (20 mM Tris-HCl, pH 7.9; 500 mM NaCl; 5 mM imidazole), then sonicated and centrifuged. The soluble fraction was applied to a 2-mL equilibrated nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen, Valencia, CA), washed, then eluted sequentially with binding buffer containing 80 mM, 100 mM, and 200 mM imidazole. The total protein in each eluted fraction was determined by Bradford assay, using bovine serum albumin (BSA) as a protein standard. Fractions were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to determine purity, then pooled and dialyzed against TENG buffer (50 mM Tris-HCl, pH 7.9; 0.1 mM EDTA; 100 mM NaCl; 20% glycerol).
Hybridoma generation and mAb production
Four female Balb/c ByJ mice (Jackson Labs, Bar Harbor, ME) were injected with purified human recombinant ERRa every fourteen days; each injection administered was approximately 50 lL subcutaneously and 50 lL intraperitoneally. The first injection contained 5 lg purified ERRa in Freund's complete adjuvant (Sigma-Aldrich, St.Louis, MO). The second and third injections contained 10 lg and 20 lg ERRa, respectively, in Freund's incomplete adjuvant (Sigma-Aldrich). The mice were bled on day 56, and the sera were assayed by ELISA and Western blot. Sera from all four mice showed a titer of at least 1:32,000 in the ELISA and reacted with overexpressed ERRa by Western blot analyses. Three days before the fusion and at least thirty days after the last injection in incomplete adjuvant, the selected mouse was injected with 50 lg of ERRa in phosphate-buffered saline (PBS), administered intraperitoneally. Hybridomas were prepared from isolated splenocytes by standard hybridoma methods [27] , using NS1 myeloma cells as the fusion partner. Twelve days after the fusion, cell culture media were assayed by standard ELISA for the presence of ERRa-reactive antibodies. Cells from the ELISA-positive wells were cloned at least twice by limiting dilution. All animal protocols were approved by the University of Wisconsin-Madison School of Medicine and Public Health Animal Use and Care Committee.
mAb purification
Antibody-producing hybridomas were grown in ascites fluid or Celline flasks (IBS Integra Biosciences, Chur, Switzerland) according to manufacturer instructions [28] , and mAbs were purified as follows. To remove albumin from IgG 1 antibodies, samples were precipitated with saturated ammonium sulfate (45% w/v), mixed on ice for twenty minutes, then incubated at 4°C for eighteen hours. Samples were collected by centrifugation, resuspended in antibody buffer (50 mM Tris-HCl, 25 mM NaCl, pH 6.9), and dialyzed into antibody buffer for eighteen hours at 4°C. Samples were applied to 4-mL equilibrated DE52 diethylaminoethyl cellulose columns (Whatman, Maidstone, England); purified mAbs were collected in the flowthrough fraction. For IgG 2a and IgG 2b mAbs, samples were diluted twofold with PBS and applied to protein A-conjugated agarose columns (Repligen, Waltham, MA). Columns were washed with PBS, after which mAbs were eluted with 0.75 M acetic acid. Eluted mAbs were neutralized by the addition of 2 M Tris-HCl pH 7.9, and mAbs were dialyzed against PBS.
ELISA and ELISA-elution
ELISA and ELISA-elution assays were performed as previously described [29] [30] [31] [32] [33] . Microtiter plates (96-well) were coated with 100 ng purified ERRa per well, then blocked in BLOTTO (1% dried nonfat milk in PBS) overnight at 4°C. Wells were washed with 0.1% Tween-20 in PBS (PBS-T), then mAbs were added to wells and incubated for one hour at 23°C. For ELISAs, plates were washed with PBS-T, then incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary antibody (American Qualex, San Clemente, CA). Bound antibody was detected using hydrogen peroxide substrate and o-phenylenediamine indicator in citrate buffer. For ELISA-elution experiments, polyol elution buffers containing various concentrations of propylene glycol and ammonium sulfate in TE buffer (50 mM Tris-HCl and 0.1 mM EDTA, pH 7.9) were added to each well and incubated at room temperature for twenty minutes. Plates were washed with PBS-T, after which any bound primary antibody was detected by reacting with secondary antibody and substrate as described above. Colorimetric analysis of ELISA and ELISA-elution was performed using an SLT Spectra plate reader.
Mammalian cell lines and transfections
Human embryonic kidney 293T cells (HEK 293T) and BT-474 mammary carcinoma cells were grown in high-glucose Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Thermo Scientific, Hudson, NH). MCF-7: WS8 (derived from the MCF-7 human mammary carcinoma cell line, kind gift from Dr. V. Craig Jordan, Georgetown University) and SK-BR-3 mammary carcinoma cells were grown in DMEM/F-12 medium supplemented with 10% FBS, 100 lM non-essential amino acids, and 6 ng/mL insulin. All cells were grown at 37°C in a humidified 5% CO 2 atmosphere. To express ERRa fragments suitable for epitope mapping, 293T cells were transiently transfected with pcDNA3.1 plasmid constructs encoding ERRa truncation mutants, designated by amino acid position: 1-78, 1-198, 77-423, and 145-423 (kind gift of Richard Kraus, UW-Madison). For crossreactivity studies, 293T cells were transiently transfected with human cytomegalovirus promoter-driven CMX expression plasmid encoding ERa, ERb, ERRa, ERRb, or ERRc (kind gifts of Dr. Wei Xu, UW-Madison). For all 293T cell transfections, 25-kDa polyethyleneimine (PEI) was used as a transfection reagent (40 lg PEI per 2.5 lg DNA per 10-cm dish of cells). To overexpress full-length ERRa in mammalian cells, MCF-7 cells were transiently transfected with CMX-ERRa or CMX empty vector, using TransIT-LT1 transfection reagent (Mirus). All transfected cells were grown at 37°C with 5% CO 2 for forty-eight hours, after which they were lysed in Freedman buffer [50 mM Tris, pH 7.5; 150 mM NaCl; 1% Nonidet P-40; 10% glycerol; 2 mM ethylenediaminetetraacetic acid (EDTA); 50 mM NaF; 1 mM phenylmethanesulfonyl fluoride (PMSF)] to generate whole-cell extracts [34] .
SDS-PAGE and Western blot, and silver staining
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), using 4-12% Bis-Tris NuPAGE gels (Invitrogen) in 2-(N-morpholino)ethanesulfonic acid (MES) running buffer. For initial Western blots detecting ERRa overexpressed in MCF-7 cells, all blocking and antibody incubation steps were performed in BLOTTO. For these studies, we used an alkaline phosphatase-conjugated goat anti-mouse secondary antibody (Millipore, Billerica, MA) and 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT) reagent as substrate. In all other Western blots, horseradish peroxidase (HRP)-conjugated light chain-specific goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch, West Grove, PA) or HRP-conjugated donkey anti-rabbit IgG secondary antibody (GE Healthcare, Piscataway, NJ) was used in concert with a chemiluminescent substrate (Thermo Scientific, Rockford, IL) for detection. In these assays, blocking and antibody incubation steps for the majority of the mAbs were performed in 5% nonfat dry milk in a Tris-buffered solution containing 0.1% Tween-20 (TBS-T); blocking and incubations for mAbs 2ERR1, 2ERR6, and 2ERR37 were performed in 3% BSA in TBS-T. For detection of endogenous ERRa by mAb 2ERR10, BT-474 cells were treated for three hours with increasing amounts of XCT790, an inverse agonist of ERRa which selectively targets the protein for degradation [43] .
Electrophoretic mobility supershift assay (EMSA)
Electrophoretic mobility supershift assays were performed as previously described [4, 8, 35, 36] . For overexpression studies, MCF-7 cells were transiently transfected with pCMX-ERRa; for examination of endogenous ERRa, BT-474 cells were used. Cells were lysed in Freeman buffer and lysate was incubated with mAb and 1 ng double-stranded radiolabeled ERRE probe (5 0 -AGCAGTGGC-GATTTGTCAAGGTCACACAGT-3 0 ; ERRE underlined) in a solution containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4; 1 mM dithiothreitol (DTT); 100 mM NaCl; 10% glycerol (v/v); 3 lg BSA; and 4 lg poly(dI-dC). Samples were loaded onto non-denaturing 5% polyacrylamide gels and electrophoresed at 200 V for two hours at 4°C. Gels were transferred to Whatman paper, dried at 80°C for one hour, then analyzed with a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA).
Immunoprecipitation (IP)
For all immunoprecipitation assays, protein G agarose (Millipore) was washed in dialysis buffer (50 mM Tris-HCl, pH 8.1; 2 mM EDTA), then blocked overnight at 4°C with 0.5 mg/mL bovine serum albumin (BSA) and 0.5 mg/mL herring sperm DNA (Promega, Madison, WI). Resin was washed and resuspended in an equal volume of dialysis buffer. For each IP, mAb was pre-bound to blocked protein G agarose in dilution buffer (16.7 mM Tris-HCl, pH 8.1; 1.2 mM EDTA; 167 mM NaCl; 1.1% Triton Â-100; 0.01% SDS; 10 mM sodium pyrophosphate). The antibody-resin complexes were washed twice with dilution buffer to remove excess antibody, then incubated overnight at 4°C with whole-cell extract from MCF-7 cells overexpressing ERRa (1 mg total protein per IP). Resins were briefly washed three times in dilution buffer, then eluted in 2Â Laemmli SDS loading buffer. Immunoprecipitated ERRa was detected by Western blot analyses, using mAb 2ERR10 as the primary antibody and a light chain-specific anti-mouse IgG secondary antibody as described above.
Chromatin immunoprecipitation (ChIP) and PCR
For ChIP assays, BT-474 cells were treated with formaldehyde to crosslink DNA and associated proteins, then lysed as described [37, 38] . Chromatin was sheared to an average size of 500 bp by sonicating samples three times for ten seconds at 9 W output using a Fisher Scientific Sonic Dismembrator 100. After sonication, chromatin was precleared with blocked protein G agarose. Each antibody was prebound to protein G agarose resin, then incubated with precleared lysate in dilution buffer overnight at 4°C. ChIP samples were washed and eluted, after which crosslinks were reversed. DNA was purified by using QiaQuick PCR purification spin columns (Qiagen). Pulldown of endogenous DNA-bound ERRa was checked by PCR, using primers designed to amplify the ESRRA promoter, which contains a characterized ERRa binding site [46] . PCR amplification was performed for 33 cycles using Go Taq reagents (Promega). Primer sequences were as follows: forward: 5-GCAGTGACCTTGAGC TTTCTCC-3; reverse: 5-GAACCGTAGACCCAGTAGCC-3.
Immunofluorescence
For immunofluorescent detection of overexpressed ERRa, MCF-7 mammary carcinoma cells were grown on round glass coverslips in 12-well plates, then transiently transfected with the pCMX-ERRa expression plasmid described above. At forty-eight hours post-transfection, cells were fixed in 3% paraformaldehyde, then permeabilized in 0.2% Triton Â-100. Permeabilized cells were incubated with purified anti-ERRa mAbs at a concentration of 20 lg/mL (twofold dilution of cell supernatants for mAbs 2ERR2 and 2ERR6) in 1.5% goat serum (Jackson ImmunoResearch) overnight at 4°C. The cells were then incubated with Alexa 488 -conjugated goat anti-mouse IgG secondary antibody (Invitrogen) and 4 0 ,6-diamidino-2-phenylindole (DAPI) nuclear counterstain (Invitrogen) for one hour at room temperature. Imaging was performed using a Leica DM5000 fluorescence microscope; all settings were conserved within each experiment. For detection of endogenous ERRa by mAb 2ERR10, cells were treated for twenty-four hours with 0.1% DMSO vehicle control or 5 lM XCT790, an inverse agonist of ERRa which selectively targets the protein for degradation [43] ; all immunocytochemistry steps were performed as described above. Imaging of endogenous ERRa was performed using a BioRad Radiance 2100 MP Rainbow confocal/multiphoton microscope, and all settings were conserved within each experiment.
mAb conjugation to Sepharose resin
Antibody-conjugated Sepharose was prepared as described previously [39] . Purified 2ERR1 antibody was dialyzed into coupling buffer (0.1 M NaHCO 3 , 0.5 M NaCl, pH 8.3) overnight at 4°C. Cyanogen bromide-activated Sepharose (GE Healthcare) was swollen in 1 mM HCl and rinsed with coupling buffer. Dialyzed 2ERR1 antibody (6 mg) was conjugated to 0.5 g dry weight Sepharose at 23°C for two hours and collected on a sintered glass filter. 2ERR1-Sepharose was mixed with blocking agent (1 M ethanolamine in coupling buffer, pH 8.0) for two hours at 23°C, followed by four sets of washes alternating coupling buffer and acetate buffer (0.1 M sodium acetate, 0.5 M NaCl, pH 4.0). 2ERR1-Sepharose was stored in TE +0.02% NaN 3 at 4°C; resin can be stored for six months and can be used multiple times if treated as described [32, 40] .
Immunoaffinity purification of ERRa using polyol-responsive mAbs 2ERR1-Sepharose was blocked with BSA and herring sperm DNA as described above, then equilibrated in Freedman buffer. Resin was incubated at 4°C for one hour with cell lysate, then washed with TE. A third wash was performed with TE +250 mM ammonium sulfate, after which ERRa was gently eluted from the column with polyol elution buffer (TE +0.75 M ammonium sulfate +40% propylene glycol). Proteins were visualized by silver staining and Western blot analyses.
Results and discussion
Monoclonal antibody (mAb) production and initial screening His 6 -tagged human ERRa protein was expressed in E. coli and purified ( Fig. 1) , then used to immunize mice for mAb production. ELISAs were used to screen sera for reactivity to purified ERRa. Spleen cells from immunoreactive mice were fused with myeloma cells to produce immortal antibody-producing hybridoma cell lines; two separate fusions generated nine high-affinity mAbs which reacted with His 6 -ERRa in ELISAs. All nine antibodies were able to detect ERRa overexpressed in MCF-7 cells by Western blot analyses ( Fig. 2A) . For mAbs 2ERR6 and 2ERR37, performing all blocking and antibody incubation steps in 3% bovine serum albumin (BSA) increased signal intensity. At least four of the mAbs (1ERR87, 1ERR90, 2ERR2, 2ERR10) were useful for detecting endogenous ERRa in 40 lg BT-474 whole-cell extract by Western blot analyses. A representative Western blot showing detection of endogenous ERRa by mAb 2ERR10 is shown in Fig. 2B. In this figure , BT-474 cells were treated with XCT790, a compound which specifically targets the ERRa protein for degradation [13, [41] [42] [43] . The major form of ERRa is a 52-kDa protein which is shown here to be degraded with increasing amounts of XCT790. In these Westerns, bands larger than 52 kDa likely indicate splice variants [4, 7] , post-translationally modified forms of the protein [2, 7] , or strongly-associated ERRa complexes [47] . The properties of the ERRa mAbs are summarized in Table 1 .
Isotyping and epitope mapping
Antibody isotyping was performed using an ELISA-based kit (HyClone, Logan, UT), and all nine mAbs were determined to be IgG subtypes. 1ERR21, 1ERR87, 1ERR90, 2ERR10, and 2ERR37 were found to be IgG 1 molecules; 2ERR1 and 2ERR2 are IgG 2a mAbs, and 2ERR6 and 2ERR7 belong to subisotype IgG 2b (summarized in Table  1 ). Next, we performed epitope mapping to determine which region of the ERRa protein is recognized by each mAb. Human embryonic kidney 293T cells were transiently transfected with plasmids encoding ERRa truncation mutants representing different regions of the protein, as indicated by amino acid position in fulllength ERRa: 1-78, 1-198, 77-423, and 145-23. Cell lysates were separated by SDS-PAGE and analyzed by Western blot. Antibodies 1ERR87, 1ERR90, 2ERR2, and 2ERR10 reacted with epitopes in the N-terminal A/B domain, while mAbs 1ERR21, 2ERR6, and 2ERR7 recognized epitopes in the C-terminal E/F domain. 2ERR37 was the only mAb which reacted with region C, which contains the DNA-binding domain (DBD). Antibody 2ERR1 was able to detect overexpressed full-length ERRa in Western blots, but its epitope could not be mapped because it did not react with any of the ERRa truncation mutants. Overall, these mAbs appear to offer broad cov-erage of the entire ERRa protein. Fig. 3A shows representative epitope mapping for mAbs 2ERR10, 2ERR37, and 1ERR21 by Western blot analyses. A schematic showing ERRa truncation mutants and mAb reactivity with regions of ERRa can be seen in Fig. 3B .
mAb reactivities with ER and ERR proteins
To test mAb reactivities with ERRa-related proteins, the known estrogen receptor and ERR isoforms were overexpressed and mAb crossreactivities were analyzed by Western blot. Human embryonic kidney 293T cells were transiently transfected with plasmids encoding empty vector or full-length ERa, ERb, ERRa, ERRb, or ERRc. Cell lysates were separated by SDS-PAGE and overexpression of each isoform was confirmed by Western blot using antibodies specific to the individual ER and ERR proteins (Fig. 4A) . The same lysates were subjected to Western blot analyses using the individual mAbs to determine their crossreactivities; representative data are shown in Fig. 4B . None of the mAbs reacted with any ER and ERR proteins other than ERRa.
Immunoprecipitation of ERRa
We overexpressed full-length ERRa in MCF-7 cells and generated whole-cell extracts for use in immunoprecipitation (IP) stud- a + indicates reactivity with overexpressed ERRa; ++ indicates ability to detect endogenous ERRa in 40 lg total protein in BT-474 whole-cell extract. Performing Western blot incubations in 3% bovine serum albumin (BSA) increased signal for 2ERR6 and 2ERR37. b Antibodies 1ERR21 and 2ERR7 could immunoprecipitate ERRa, but not as well as those mAbs marked ++. c All mAbs marked + could shift both overexpressed and endogenous ERRa. d 2ERR7 gave a significantly more robust pulldown than the other single mAbs (indicated by ++). We found that mixtures of mAbs 1ERR21 and 1ERR87 with mAb 2ERR1 or 2ERR10 gave a pulldown comparable to that of 2ERR7. e 2ERR10 was able to detect both overexpressed and endogenous ERRa (as indicated by ++). f Polyol-responsiveness indicates the ability of each mAb to release ERRa under gentle eluting conditions as determined by ELISA-elution. ies. Antibody subisotype is an important consideration when choosing resins for IP applications; since protein G binds all mouse IgG subisotypes, we used protein G-conjugated agarose in all IP experiments. Those antibodies reacting with N-terminal epitopes (1ERR87, 1ERR90, 2ERR2, and 2ERR10) as well as polyol-responsive mAb 2ERR1 were able to pull down significant quantities of ERRa (Fig. 5) . Antibodies 1ERR21 and 2ERR7 did not work as well in this assay but were able to immunoprecipitate detectable amounts of ERRa. 2ERR6 and 2ERR37 IPs gave no detectable signal. It is worth noting that these four weakly-or non-immunoprecipitating mAbs (1ERR21, 2ERR6, 2ERR7, and 2ERR37) interact with the E/F region of the protein; it may be that these C-terminal epitopes are inaccessible when ERRa is in its native conformation.
EMSA supershift of DNA-bound ERRa
Each antibody was tested for its ability to react with DNA-bound ERRa in electrophoretic mobility supershift assays (EMSAs). Lysates from MCF-7 cells overexpressing ERRa were incubated with mAb and a 32 P-labeled estrogen-related response element (ERRE) DNA probe, after which samples were run on a non-denaturing gel. Nterminal IgG 1 antibodies (1ERR87, 1ERR90, and 2ERR10) and mAb 2ERR1 were able to supershift DNA-bound ERRa, as shown in Fig. 6 . These four antibodies could also supershift endogenous ERRa in BT-474 whole-cell lysates (Fig. 6B ).
Chromatin immunoprecipitation (ChIP) of endogenous DNA-bound ERRa
Next, we evaluated antibody effectiveness in pulling down endogenous DNA-bound ERRa in chromatin immunoprecipitation (ChIP) assays. For these studies, we used the BT-474 mammary carcinoma cell line, which endogenously expresses high levels of ERRa. Conditions for the assay were optimized based on established protocols [37, 38] . We tested each of the antibodies at various concentrations and found that the majority of mAbs could immunoprecipitate chromatin-bound ERRa as determined by PCR amplification of the ESRRA promoter (Fig. 7) . It is of interest to note that those mAbs capable of supershifting DNA-bound ERRa in EMSAs were not necessarily useful in the ChIP assay and vice versa. 2ERR7 gave the best pulldown, while mAbs 1ERR90 and 2ERR37 did not appear to work well in this assay. We investigated the possibility that using a ''cocktail'' consisting of several mAbs recognizing different epitopes might improve pulldown efficiency. We tested various combinations of these antibodies and determined that mAbs 1ERR21 and 1ERR87, combined with either 2ERR1 or 2ERR10, enhanced pulldown of ERRa in the ChIP assay. Using several mAbs in concert may be advantageous because it could permit isolation of certain ERRa complexes which cannot be detected by a 
Immunofluorescent detection of ERRa
We performed immunofluorescence assays in MCF-7 cells overexpressing ERRa to determine the usefulness of these antibodies in detecting ERRa. Six of the nine mAbs -1ERR87, 1ERR90, 2ERR1, 2ERR2, 2ERR10, 2ERR37 -were able to detect overexpressed ERRa in the nuclei of formalin-fixed cells with high signal intensity and low background (Fig. 8A) . mAb 2ERR10 could also detect endogenous ERRa. In order to test the specificity of 2ERR10 for endogenous ERRa, we cultured three different mammary carcinoma cell lines (BT-474, MCF-7, and SK-BR-3) in the presence or absence of XCT790. We found that XCT790-mediated knockdown of ERRa significantly diminished nuclear staining, indicating that 2ERR10 specifically detects endogenous ERRa in this assay (Fig. 8B) . This mAb may prove to be useful in clinical applications for the detection of ERRa in formalin-fixed human tissue samples.
Determination of mAb polyol-responsiveness by ELISA-elution
Our lab has discovered that certain high-affinity antibodies possess the ability to release antigen in the presence of a low-molecular-weight polyhydroxylated compound (polyol) and nonchaotropic salt. This property can be employed to specifically and efficiently isolate proteins which retain native structure and biological activity [32, 40] . Polyol-responsive mAbs (PR-mAbs) have been utilized to isolate protein complexes of sufficient purity and yield for crystallization and for identification of novel interacting partners [31, 33, 39, 44, 45] . BT-474 cells were formaldehyde-fixed to crosslink protein-DNA complexes, then lysed. Lysates were sonicated to fragment chromatin, then incubated with Sepharose-bound mAbs. Protein-chromatin complexes bound to the resin were washed and eluted, after which crosslink reversal and DNA purification steps were performed. Pulldown by mAbs was assessed by PCR amplification of the proximal promoter of the ESRRA gene, an established ERRa binding site [46] . Cocktail #1 consisted of mAbs 1ERR21, 1ERR87, and 2ERR1; cocktail #2 consisted of mAbs 1ERR21, 1ERR87, and 2ERR10.
We estimate that about 10% of mAbs are polyol-responsive; the mechanism and mAb characteristics contributing to this property remain unclear.
We performed modified enzyme-linked immunosorbent assays (ELISA-elutions) to screen for mAbs that gently release ERRa in the presence of 40% propylene glycol and 0.75 M ammonium sulfate. Five mAbs showed varying degrees of polyol-responsiveness in this assay (Fig. 9A ). 1ERR21 and 2ERR10 were weakly polyolresponsive, retaining about 70% signal when compared with the TE control. Our lab has determined that even weakly polyolresponsive mAbs can perform efficiently in immunoaffinity applications (unpublished data). Antibodies 2ERR1, 2ERR6, and 2ERR37 are strongly polyol-responsive, showing significantly reduced signal in the presence of polyol elution buffer when compared with TE vehicle control. Of these, we focused on 2ERR1 for further investigation because it reacts strongly with ERRa in a variety of assays, including immunoprecipitation. The affinity of 2ERR1 for ERRa is affected somewhat by the presence of propylene glycol or ammonium sulfate alone; however, the combination of salt and polyol has a synergistic effect, causing more than 80% of the mAb to release its antigen in 40% propylene glycol at a relatively low concentration of salt. A detailed analysis of 2ERR1 responsiveness to increasing concentrations of polyol and salt is shown in Fig. 9B . Fig. 9 . Polyol-responsiveness of anti-ERRa mAbs. ELISA-elution assays were performed to identify polyol-responsive mAbs (PR-mAbs). Antibodies were bound to ERRacoated wells in 96-well plates, then incubated in TE control buffer or salt-polyol buffer containing ammonium sulfate (AS) and propylene glycol (PG). Bound mAb was detected with HRP-conjugated anti-mouse secondary antibody and peroxide substrate, and colorimetric analysis was performed. Polyol-responsivity was determined by comparing signal in the presence and absence of salt-polyol, given as a percentage of TE control buffer; PR-mAbs have lower affinity for antigen in salt-polyol buffer, which results in diminished signal. Antibodies are considered polyol-responsive if they show greater than 50% reduction in signal when compared to TE buffer control, as indicated in Table 1 . (A) Antibodies were bound to ERRa, then incubated in TE control buffer or salt-polyol buffer containing 0.75 M ammonium sulfate (AS) and 40% propylene glycol (PG). Signal reduction resulting from elution of mAbs in the presence of salt and polyol is shown as a percentage of TE buffer control. (B) The ability of mAb 2ERR1 to bind ERRa in response to increasing concentrations of ammonium sulfate and propylene glycol (PG) was tested. Each condition was assayed in triplicate within an experiment. Data are shown the average of these technical replicates within one experiment, and error bars represent the standard deviation of these. Data are representative of three independent experiments.
Gentle immunoaffinity chromatography (IAC) purification of overexpressed and endogenous ERRa
Immunoaffinity chromatography (IAC) is a powerful tool which can isolate proteins rapidly and specifically in a single purification step; however, this approach usually requires harsh eluting conditions which can denature proteins, rendering them inactive. Gentle IAC using PR-mAbs facilitates recovery of active proteins in native conformations and complexes. In order to purify ERRa using gentle IAC, we covalently attached 2ERR1 to cyanogen bromide-activated Sepharose and used this column to purify ERRa from mammalian cell lysates in a single chromatographic step. Figs. 10A and B show IAC fractionation of lysate from MCF-7 cells overexpressing ERRa (silver-stained polyacrylamide gel and Western blot, respectively).
As expected, ERRa remained bound to the 2ERR1 resin until eluted with salt-polyol buffer. The eluates show a significant purification of ERRa, which is the major band in the fraction as determined by silver-staining. The other bands present in this fraction likely consist of ERRa-interacting proteins. In addition to isolating overexpressed ERRa, we were able to use gentle immunoaffinity chromatography to purify endogenous ERRa from BT-474 cell lysate (Fig. 10C) .
Conclusions
These characterization studies demonstrate that high-affinity anti-ERRa mAbs are suitable for the detection and purification of ERRa in a variety of biochemical assays. Of the nine monoclonal Fig. 10 . Purification of ERRa by gentle immunoaffinity chromatography (IAC). 2ERR1-conjugated Sepharose was incubated with whole-cell lysate, then washed. ERRa was gently eluted from the column with polyol elution buffer (TE + 0.75 M ammonium sulfate +40% propylene glycol). IAC fractions were loaded on polyacrylamide gels in proportion to fraction volumes, separated by SDS-PAGE, then prepared for silver staining or Western blot. Western blots were probed with mAb 2ERR10 followed by a light chain-specific anti-mouse secondary antibody to avoid detection of mAb heavy chain present in the samples. (A) A 2-mL column was loaded with lysate containing 8 mg total protein harvested from MCF-7 cells overexpressing ERRa. Samples were loaded on a polyacrylamide gel in proportion to fraction volumes. Molecular weight (in kDa) is indicated at left. TE designates Tris-EDTA buffer; AS signifies 0.25 M ammonium sulfate. (B) The sample set in Fig. 10A was subjected to Western blot analysis to confirm the presence of ERRa in IAC fractions. (C) For purification of endogenous ERRa, a 1-mL column was loaded with BT-474 cell lysate containing 15 mg total protein. ERRa was detected by Western blot.
antibodies investigated, mAbs 1ERR87, 2ERR1, and 2ERR10 seem to have the highest affinities for ERRa and were effective in all assays tested. We found that using mAb ''cocktails'' -mixtures of mAbs which recognize different epitopes -had a synergistic effect in ChIP, and this approach may be applicable to other assays. Sequential use of different mAbs in tandem purifications could be useful for sorting ERRa subpopulations associated with splice variants, post-translational modifications, or interacting partners. We determined that 2ERR1 is strongly polyol-responsive and that immunoprecipitated ERRa can be gently eluted in the presence of polyol and salt. 2ERR1-mediated gentle immunoaffinity chromatography could be useful for crystallization of ERRa, mass spectrometric analyses of post-translational modifications and ERRa-interacting proteins, and other purification-based strategies. We anticipate that these high-affinity immunological reagents will be useful in a range of novel research and clinical applications.
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